- ReWalk just barely met its 2021 revenue targets at $6 million for the year, but was still dealing with Covid-19 restrictions impacting the sales process for much of the year.
- A ruling in the 5-year-old appeal by an insurer in the German federal social court seems to be imminent within the next 30 to 120 days.
- ReWalk is preparing to pursue a coverage determination with the Centers for Medicare and Medicaid, building on the progress of getting the HCPCS code for billing exoskeletons in 2020.
For further details see:
ReWalk Robotics: Catalysts On The Horizon